tiprankstipranks
Advertisement
Advertisement
UroGen Pharma Earnings Call Highlights ZUSDURI Surge
PremiumCompany AnnouncementsUroGen Pharma Earnings Call Highlights ZUSDURI Surge
1M ago
UroGen Pharma: Buy Rating Reiterated as Strong ZUSDURI Data and UGN-103 Pipeline Support Unchanged $45 Price Target
Premium
Ratings
UroGen Pharma: Buy Rating Reiterated as Strong ZUSDURI Data and UGN-103 Pipeline Support Unchanged $45 Price Target
1M ago
UroGen Pharma reports month results from UTOPIA trial
Premium
The Fly
UroGen Pharma reports month results from UTOPIA trial
1M ago
UroGen Pharma price target raised to $40 from $34 at Oppenheimer
PremiumThe FlyUroGen Pharma price target raised to $40 from $34 at Oppenheimer
2M ago
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
Premium
The Fly
UroGen Pharma reports Q1 EPS (47c), consensus (36c)
2M ago
Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
Premium
Ratings
Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
2M ago
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
PremiumRatingsBuilding Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
4M ago
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
Premium
Company Announcements
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
4M ago
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
Premium
Ratings
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100